AH_Logo_Color(notag)@4x.png
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®
04. März 2025 10:00 ET | AscellaHealth, LLC
Optime Care has expanded partnership with Eton Pharmaceuticals to serve as the SP provider for GALZIN®, an FDA-approved treatment for Wilson Disease.
22157.jpg
3 Day Pharma Mini MBA Training Course: Strategic Thinking, Leadership Growth, and Practical Solutions for Pharma/Biotech Professionals (ONLINE EVENT: March 19-21, 2025)
26. Februar 2025 09:50 ET | Research and Markets
Dublin, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The "The Pharma Mini MBA Training Course" conference has been added to ResearchAndMarkets.com's offering. A 'must-attend' for professionals in the...
NotifiedPR_Image_MAR-178-021925.1
AscellaHealth Expands Leadership Team to Accelerate Growth, Strengthen Operations and Advance Patient-Centric Solutions
25. Februar 2025 13:00 ET | AscellaHealth, LLC
AscellaHealth announces the appointment of two senior leaders: Clayton Edwards, RPh, MBA and Carl T. Bertram, PharmD, MS, MBA
PipelineDigest_2024Q4_Article_MAR-152-010325.1
AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals
09. Januar 2025 10:00 ET | AscellaHealth, LLC
AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals
Fill Finish
Fill Finish Pharmaceutical Contract Manufacturing Market Trends and Global Forecasts, 2024-2035: Growing Drug Pipelines Catalyze Expansion of Pharmaceutical Fill-Finish Contract Manufacturing
02. Dezember 2024 04:15 ET | Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Fill Finish Pharmaceutical Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Fill Finish Service...
Deloitte_Fast500_2024_Stacked
AscellaHealth Ranked Number 154 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
21. November 2024 10:03 ET | AscellaHealth, LLC
2024 Deloitte Technology Fast 500™ Ranks AscellaHealth Number 154 with 753% Revenue Growth
AscellaHealth Pipeline Digest
AscellaHealth Releases Q3 2024 Specialty & Rare Pipeline Digest™: FDA-Approved Biosimilars Outpaces Cell and Gene Therapy Amid Complex Regulatory Challenges
22. Oktober 2024 10:00 ET | AscellaHealth, LLC
BERWYN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today released its latest...
AH_Logo_Color(notag)@4x.png
AscellaHealth Announces its Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services
17. Oktober 2024 06:00 ET | AscellaHealth, LLC; CHAPPER healthcare
AscellaHealth Announces Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services
AH_Logo_Color(notag)@4x.png
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
16. Oktober 2024 10:00 ET | AscellaHealth, LLC
Optime Care Broadens Partnership with Rigel Pharmaceuticals for Expanded Commercial Distribution of TAVALISSE®
U.S. Regulatory Affairs Market
U.S. Regulatory Affairs Market Size, Share & Trends Analysis Report 2024-2030 by Services, Category, Indication, Product Stage, Service Provider, Company Size, End-use
11. Juli 2024 10:45 ET | Research and Markets
Dublin, July 11, 2024 (GLOBE NEWSWIRE) -- The "U.S. Regulatory Affairs Market Size, Share & Trends Analysis Report by Services, Category, Indication, Product Stage, Service Provider, Company...